Abbott Expands Pharmaceutical Pipeline With $3.7 Bil Kos Acquisition
Executive Summary
Abbott's proposed $3.7 bil. acquisition of Kos Pharmaceuticals will help diversify Abbott's existing cardiovascular franchise, and could also expand its pipeline into respiratory diseases
You may also be interested in...
Lilly Expects Experience To Help Avoid Mistakes Of Pfizer’s Exubera Launch
Lilly's experience in the diabetes marketplace is one of the factors that fuels company optimism about its AIR inhaled insulin product, for which the company has an NDA submission goal of 2009, CEO Sidney Taurel told the Bear Stearns Healthcare Conference in New York, Sept. 11
Lilly Expects Experience To Help Avoid Mistakes Of Pfizer’s Exubera Launch
Lilly's experience in the diabetes marketplace is one of the factors that fuels company optimism about its AIR inhaled insulin product, for which the company has an NDA submission goal of 2009, CEO Sidney Taurel told the Bear Stearns Healthcare Conference in New York, Sept. 11
Abbott Cardiovascular Franchise Swells; Combo Waves Will Crest in 2009
Abbott plans to submit a fixed-dose statin-fenofibrate combination with AstraZeneca's Crestor in 2009, the company reported during a June 18 sales and earnings call